Redeye provides an update on Biovica following the Q3 2025/2026 report, which overall came in slightly better than expected. As a result of the lower costs than estimated, we lower our near-term OPEX estimates. However, we pencil in an equity issue in our model, in line with Redeye policy, but note that the company is in no need for capital in the near term. All in all, we arrive at a lowered valuation range.
LÄS MER
